Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

The Windows Start menu is getting its first major redesign since 2021 and will be rolled out to everyone with the November 11 Patch Tuesday update. The Start menu is now scrollable, so you can move ...

Bethesda has outlined the patch notes for Fallout 4 ahead of the release of the Creations Menu update and Anniversary Edition. During the recent Fallout Day broadcast, Bethesda announced Fallout 4 ...

Microsoft has started rolling out the new Start menu for Windows 11, which we previously did a deep dive preview on. Both versions 24H2 and the newer 25H2 of Windows 11 can use the new Start menu.

(Reuters) -Lexicon Pharmaceuticals said on Monday the U.S. Food and Drug Administration requires more time to review the company's previously submitted additional data on its experimental drug, ...

IHOP is offering customers a new way to enjoy their breakfast favorites that's easy on the wallet. The company announced on Monday, Sept. 15, that it's introducing an everyday value menu as part of ...

A Houston-area company has just inked a massive, $1 billion deal to become the next big weight-loss medication maker. The timeline for the company to begin receiving payments is dependent on the ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...

March 28 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is licensing Lexicon Pharmaceuticals' (LXRX.O), opens new tab experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist, Wegovy. It’s found a contender with preclinical data indicating it can lead to ...

Lexicon eligible to receive up to $1 billion in upfront and development, regulatory and sales milestone payments, including $75 million in upfront and near-term milestone payments THE WOODLANDS, Texas ...

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) stock is trading higher on Friday. Penny stock Lexicon Pharmaceuticals entered into an exclusive license agreement with Novo Nordisk A/S (NYSE:NVO) on Friday ...